vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $270.7M, roughly 1.1× BALCHEM CORP). BALCHEM CORP runs the higher net margin — 14.9% vs 12.8%, a 2.0% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs -6.4%). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs 4.2%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
BCPC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $295.9M |
| Net Profit | $40.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 20.5% | 18.4% |
| Net Margin | 14.9% | 12.8% |
| Revenue YoY | 8.1% | -6.4% |
| Net Profit YoY | 8.7% | 68.3% |
| EPS (diluted) | $1.25 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $295.9M | ||
| Q3 25 | $267.6M | — | ||
| Q2 25 | $255.5M | $317.0M | ||
| Q1 25 | $250.5M | $316.2M | ||
| Q4 24 | $240.0M | $297.0M | ||
| Q3 24 | $239.9M | $289.5M | ||
| Q2 24 | $234.1M | $306.1M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $38.0M | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $38.3M | $-17.7M | ||
| Q1 25 | $37.1M | $22.6M | ||
| Q4 24 | $33.6M | $34.9M | ||
| Q3 24 | $33.8M | $33.6M | ||
| Q2 24 | $32.1M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 64.6% | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | 62.7% | ||
| Q1 25 | 35.2% | 67.9% | ||
| Q4 24 | 36.0% | 65.3% | ||
| Q3 24 | 35.6% | 63.2% | ||
| Q2 24 | 35.5% | 66.4% |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 18.4% | ||
| Q3 25 | 20.4% | — | ||
| Q2 25 | 20.1% | -7.5% | ||
| Q1 25 | 20.4% | 12.2% | ||
| Q4 24 | 19.8% | 16.0% | ||
| Q3 24 | 20.0% | 13.8% | ||
| Q2 24 | 19.6% | 15.0% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | 12.8% | ||
| Q3 25 | 15.1% | — | ||
| Q2 25 | 15.0% | -5.6% | ||
| Q1 25 | 14.8% | 7.1% | ||
| Q4 24 | 14.0% | 11.7% | ||
| Q3 24 | 14.1% | 11.6% | ||
| Q2 24 | 13.7% | 13.3% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $0.24 | ||
| Q3 25 | $1.24 | — | ||
| Q2 25 | $1.17 | $-0.11 | ||
| Q1 25 | $1.13 | $0.14 | ||
| Q4 24 | $1.03 | $0.22 | ||
| Q3 24 | $1.03 | $0.21 | ||
| Q2 24 | $0.98 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.3B | $2.0B |
| Total Assets | $1.7B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $172.9M | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $65.4M | $162.2M | ||
| Q1 25 | $49.9M | $140.7M | ||
| Q4 24 | $49.5M | $177.5M | ||
| Q3 24 | $73.7M | $187.5M | ||
| Q2 24 | $63.7M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | $1.9B | ||
| Q1 25 | $1.2B | $2.0B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.2B | $2.1B | ||
| Q2 24 | $1.1B | $2.1B |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | — |
| Free Cash FlowOCF − Capex | $33.8M | — |
| FCF MarginFCF / Revenue | 12.5% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | — | ||
| Q3 25 | $65.6M | — | ||
| Q2 25 | $47.3M | $98.2M | ||
| Q1 25 | $36.5M | $41.1M | ||
| Q4 24 | $52.3M | $84.3M | ||
| Q3 24 | $51.3M | $63.9M | ||
| Q2 24 | $45.0M | $75.5M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | — | $54.7M | ||
| Q2 24 | — | $57.5M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | 18.8% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | 5.9% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | 1.82× | ||
| Q4 24 | 1.56× | 2.42× | ||
| Q3 24 | 1.52× | 1.90× | ||
| Q2 24 | 1.40× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
